Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Medtronic
Dow
Johnson and Johnson
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Valbenazine tosylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for valbenazine tosylate and what is the scope of freedom to operate?

Valbenazine tosylate is the generic ingredient in one branded drug marketed by Neurocrine and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Valbenazine tosylate has thirty-two patent family members in eighteen countries.

One supplier is listed for this compound.

Summary for valbenazine tosylate
International Patents:32
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 2
Patent Applications: 2
DailyMed Link:valbenazine tosylate at DailyMed
Pharmacology for valbenazine tosylate
Synonyms for valbenazine tosylate
(2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-benzo(a)quinolizin-2-yl L-valinate bis(4-methylbenzenesulfonate)
1639208-54-0
5SML1T733B
CHEMBL3707248
D10999
Ingrezza (TN)
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester, 4-methylbenzenesulfonate (1:2)
NBI-98854 ditosylate
SCHEMBL18863051
UNII-5SML1T733B
Valbenazine ditosylate
Valbenazine tosylate (USAN)
Valbenazine tosylate [USAN]

US Patents and Regulatory Information for valbenazine tosylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-001 Apr 11, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Neurocrine INGREZZA valbenazine tosylate CAPSULE;ORAL 209241-002 Oct 4, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Express Scripts
Harvard Business School
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.